The DOI matches its Crossref record; 410 of the 410 references it cites were found in a registry or an index.
EGFR signaling pathway as therapeutic target in human cancers
Open accessAbstract
Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand orchestrator of epithelial transformation, and hence one of the most world-wide studied tyrosine kinase receptors involved in neoplasia, in several tissues. In the last decades, EGFR-targeted therapies shaped the new era of precision-oncology. Despite major advances, the dream of converting solid tumors into a chronic disease is still unfulfilled, and long-term remission eludes us. Studies investigating the function of this protein in solid malignancies have revealed numerous ways how tumor cells dysregulate EGFR function. Starting from preclinical models (cell lines, organoids, murine models) and validating in clinical specimens, EGFR-related oncogenic pathways, mechanisms of resistance, and novel avenues to inhibit tumor growth and metastatic spread enriching the therapeutic portfolios, were identified. Focusing on non-small cell lung cancer (NSCLC), where EGFR mutations are major players in the adenocarcinoma subtype, we will go over the most relevant discoveries that led us to understand EGFR and beyond, and highlight how they revolutionized cancer treatment by expanding the therapeutic arsenal at our disposal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 401–410 of 410
Schmidt‐Glenewinkel, H., Reinz, E., Bulashevska, S., Beaudouin, J., Legewie, S., Alonso, Á., & Eils, R. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.02.041 · Cited by 14
Bie, Y., Wang, J., Xiong, L., Wang, D., Liao, J., Zhang, Y., & Lin, H. (2021) · Medicine · doi:10.1097/md.0000000000024793 · Cited by 14
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients
Malapelle, U., Pilotto, S., Reale, M. L., Passiglia, F., Pisapia, P., Pepe, F., Belluomini, L., Galetta, D., Cortinovis, D. L., Tiseo, M., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103536 · Cited by 13
Storti, B., Civita, S., Faraci, P., Maroni, G., Krishnan, I., Levantini, E., & Bizzarri, R. (2019) · Biophysical Chemistry · doi:10.1016/j.bpc.2019.106225 · Cited by 12
Self-citationYin, L., Zhang, Y., Yin, L., Ou, Y., Lewis, M. S., Wang, R., Zhau, H. E., Zhou, Q., & Chung, L. W. K. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-1095 · Cited by 12
Yu, Y., Wang, Y., Wu, L., Xu, X., Zhou, H., Wang, Q., & Zhou, J. (2021) · Medicine · doi:10.1097/md.0000000000023712 · Cited by 10
Is miR therapeutic targeting still a miRage?
Levantini, E. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/4979 · Cited by 7
Self-citationVerheijen, R. B., van Duijl, T. T., van den Heuvel, M. M., Vessies, D. C. L., Muller, M., Beijnen, J. H., Janssen, J. M., Schellens, J. H. M., Steeghs, N., van den Broek, D. A., et al. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04230-4 · Cited by 6
Casas, C. M. D. L., Garzón‐Ibáñez, M., Jordana‐Ariza, N., Viteri, S., Moya‐Horno, I., Karachaliou, N., Yeste, Z., Campos, R., Villatoro, S., Balada‐Bel, A., et al. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.10.12 · Cited by 5
Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer
Fujita, K., Nakayama, M., Sata, M., Nagai, Y., Hisata, S., Mato, N., Suzuki, T., Bando, M., Hizawa, N., & Hagiwara, K. (2021) · Cancer Medicine · doi:10.1002/cam4.4330 · Cited by 2
Cited by
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C. (2025) · Cancers · doi:10.3390/cancers17172804 · Cited by 32
Metadata
- Authors
- Levantini, E., Maroni, G., Del Re, M., & Tenen, D. G.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2022-10
- Volume
- 85
- Pages
- 253-275
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W4223622421
- Cited by
- 356
- References
- 410
- FWCI
- 38.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.